Grapiprant

Drug Profile

Grapiprant

Alternative Names: 423; AAT-007; ARY 007; CJ-023; CJ-023,423; CJ-23423; MR-10A7; RQ-00000007; RQ-7

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer AskAt; Kyn Therapeutics; Maruishi Pharmaceutical
  • Class Analgesics; Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Benzene derivatives; Imidazoles; Pyridines; Small molecules; Sulfonamides; Sulfonylureas
  • Mechanism of Action Epidermal growth factor inhibitors; Interleukin 23 inhibitors; Interleukin 6 inhibitors; Interleukin-17 inhibitors; Prostaglandin E EP4 receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Acute pain; Autoimmune disorders; Cancer pain; Hypersensitivity; Inflammation; Postoperative pain

Most Recent Events

  • 05 Feb 2018 Kyn Therapeutics plans a phase Ib trial for cancer
  • 14 Dec 2017 Preclinical trials in Cancer in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute pain in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top